Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari Sells 14,000 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the sale, the chief operating officer now owns 88,975 shares of the company’s stock, valued at $1,622,904. This trade represents a 13.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Kiniksa Pharmaceuticals Trading Down 2.3 %

NASDAQ:KNSA opened at $18.39 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -131.35 and a beta of 0.29. The business’s fifty day moving average price is $20.76 and its 200 day moving average price is $23.21.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 67.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.20) EPS. Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Evercore ISI upped their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Wedbush restated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Monday. Finally, JPMorgan Chase & Co. raised their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $36.60.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. Wellington Management Group LLP acquired a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth $1,192,000. Dimensional Fund Advisors LP grew its stake in Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after purchasing an additional 157,741 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth about $675,000. Parkman Healthcare Partners LLC increased its position in Kiniksa Pharmaceuticals by 16.7% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after purchasing an additional 108,102 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Kiniksa Pharmaceuticals by 159.8% during the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after purchasing an additional 382,539 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.